Tumor Induction with the N'-Acetyl Derivative of 4-Hydroxymethylphenylhydrazine, a Metabolite of Agaritine of *Agaricus bisporus*¹

Bela Toth, Donald Nagel, Kashinath Patil, James Erickson, and Kenneth Antonson

The Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 68105

ABSTRACT

N'-Acetyl-4-(hydroxymethyl)phenylhydrazine was administered as a 0.0625% solution in drinking water continuously for the life span of Swiss mice, from 6 weeks of age. Compared to that in untreated controls, in treated animals the lung tumor incidence rose from 15 to 34% in females and 22 to 48% in males, whereas the incidence of blood vessel tumors increased from 8 to 32% in females and from 5 to 30% in males. Histopathologically, the tumors were classified as adenomas and adenocarcinomas of the lungs and angiomas and angiosarcomas of the blood vessels.

The commonly eaten mushroom Agaricus bisporus contains β -N-[γ -L(+)-glutamyl]-4-hydroxymethylphenylhydrazine, which under certain conditions yields 4-hydroxymethylphenylhydrazine and L-glutamic acid. Since 4-hydroxymethylphenylhydrazine is relatively unstable, its acetyl derivative was synthesized for this study. The possible environmental significance of the findings is discussed.

INTRODUCTION

The commercially cultivated mushroom Agaricus bisporus contains β -N-[γ -L(+)-glutamyl]-4-hydroxymethylphenylhydrazine (agaritine) (2, 5). Sporophores of the mushroom contain the enzyme γ -glutamyltransferase, which catalyzes the hydrolysis of agaritine to L-glutamate and 4-hydroxymethylphenylhydrazine (3, 5). This cleavage also occurs under mild acidic conditions (5). 4-Hydroxymethylphenylhydrazine is a relatively unstable compound; therefore it appeared promising to attach an acetyl group to it to render the compound feasible for biological experiments. The instability of 4-hydroxymethylphenylhydrazine has been attributed to the facile 1.4 elimination of water across the phenyl ring. The loss of water in agaritine is minimized by the electron-withdrawing γ -carbonyl group of the glutamic acid. The carbonyl group in AMPH² provides a similar stabilization. The similar substitution of the hydrazine moiety in agaritine and AMPH suggests a comparable electronic configuration and hence an analogous chemical reactivity for this portion of the molecule.

The present work is also part of the concentrated effort to reveal the possible tumorigenic potencies of hydrazine analogs. This class of chemicals, whether synthetic and/or naturally occurring, is apparently widely distributed in the environment (5, 6, 8, 10, 11, 14); therefore the human population is exposed to them to a considerable degree. This report records the tumorigenicity of AMPH administered continuously in drinking water for the life of albino Swiss mice.

MATERIALS AND METHODS

Albino Swiss mice from a colony randomly bred by us since 1951 were used in these experiments. They were housed in plastic cages with granular cellulose bedding, separated according to sex in groups of 10, and given Wayne Lab Blox diet in regular pellets (Allied Mills, Inc., Chicago, III.) and tap water or the chemical solution *ad libitum* as described below. The chemical used was AMPH (Chart 1; M.W., 180.21; m.p., 124.5–125.5°; purity; >97%), which was synthesized in this laboratory in the following way.

p-(N'-Acetylhydrazino)benzoic Acid

A suspension of 100 g (0.66 mole) p-hydrazinobenzoic acid in 700 ml ethyl acetate was magnetically stirred while 62 ml (0.67 mole) acetic anhydride was slowly added. After stirring for 20 min, the mixture was filtered, and the precipitate was washed with anhydrous ether. Recrystallization from methanol-water gave white needles. (m.p., 220-221°) in 75% yield.

Nuclear magnetic resonance (CDCI₃): δ 7.78 and 6.72 (AB quartet, 4 aromatic hydrogen atoms, J, 8 Hz), 4.25 (broad shoulder, 3 H, NH, and OH), and 1.94 (shoulder, 3H, CH₃). Mass spectrum, *m*/*e*: 194 (m⁺), 152 (m - C₂H₂O), and 136 (m - C₂H₄ON).

C₀H₁₀N₂O₃ Calculated: C 55.66, H 5.20, N 14.53 Found: C 55.86, H 5.26, N 14.34

N-Acetyl-N'-(p-hydroxymethyl)phenylhydrazine

A solution of 25 g (0.13 mole) of p-(N'-acetylhydrazino)benzoic acid and 500 ml of tetrahydrofuran was mechanically stirred under nitrogen at 5°, while 400 ml of a 1 M solution (0.4 mole) of diborane in tetrahydrofuran (Aldrich Chemical Co., Inc., Milwaukee, Wis.) was added dropwise at such a rate that the temperature did not rise above 10°. Stirring was continued for one-half hr after the addition was completed, and 400 ml of 1 N NaOH were added dropwise. The mixture was stirred overnight, while it was slowly warming to room temperature. Solid potassium carbonate was added until 2 distinct phases appeared

¹ This work was supported by USPHS Contract NO1 CP33278 from the National Cancer Institute, NIH. This study was presented in part at the 68th Annual Meeting of the American Association for Cancer Research, Denver, Colo., May 21, 1977 (17).

^{*} The abbreviation used is: AMPH, N'-acetyl-4-(hydroxymethyl)phenylhydrazine.



(pH, =10; aqueous layer). The aqueous layer was extracted 3 times with equivalent volumes of ether. The extracts were combined with the original organic phase and dried over sodium sulfate. Concentration in vacuo resulted in a tan residue, which was recrystallized from tetrahydrafuranether to yield 70% N-acetyl-N'-(p-hydroxymethyl)phenylhydrazine (m.p., 125-126°).

Nuclear magnetic resonance (CD₃OD): δ 7.16 and 6.74 (AB quartet, 4 aromatic hydrogens, J, 8 Hz), 4.73 (shoulder, 3H, NH and OH), 4.46 (shoulder, 2H, CH2) and 2.00 (shoulder, 3H, CH₃).

> C₉H₁₂N₂O₂ Calculated: C 59.98, H 6.66, N 15.54 Found: C 59.82, H 6.80, N 15.36

Toxicity studies were carried out with AMPH prior to the chronic experiment. Five dose levels of AMPH, 0.5, 0.25, 0.125, 0.0625, and 0.03125%, were administered in the drinking water daily for 35 days. Each group consisted of 8 animals, 4 females and 4 males. By taking into account 4 parameters, survival rates, body weights, chemical consumption figures, and histological changes, the 0.0625% level was found to be suitable for the lifelong treatment. Above the 0.0625% dose level, most of the animals died, their body weights decreased, and the chemical consumption figures were substantially lower than those of the controls. Histopathologically, vacuolated liver cells, congested lungs, and marked cellular activity in the glomeruli were observed. This toxicity technique was developed in this laboratory (12).

The solution was prepared 3 times weekly, and the total consumption of water containing AMPH was measured at the same intervals during the treatment period. The solution was placed in brown bottles because of the possible light sensitivity of the chemical. The chronic experimental group and the controls were the following.

Group 1. AMPH was dissolved in the drinking water as a 0.0625% solution and was given for the life spans of 50 female and 50 male mice that were 6 weeks (42 days) old at the beginning of the experiment. The average daily water consumption of the treated animals was 10.2 ml for the females and 10.6 ml for the males. Therefore, the average daily intake of AMPH was 6.4 mg for a female and 6.6 mg for a male.

Group 2. As untreated controls, 100 female and 100

male mice received tap water and were observed from weaning time (5 weeks of age).

The experimental and control animals were carefully checked and weighed weekly, and the gross pathological changes were recorded. The animals either were allowed to die or were killed with ether when found in poor condition. Complete necropsies were performed on all animals. All organs were examined macroscopically and were fixed in 10% buffered formalin. The liver, spleen, kidneys, bladder, thyroid, heart, pancreas, testes, ovaries, brain, nasal turbinal, at least 4 lobes of the lungs of each mouse, and organs showing gross pathological changes were studied histologically. Sections from these tissues were stained routinely with hematoxylin and eosin.

RESULTS

The survival rates after weaning are recorded in Table 1. As can be seen from the data, there is no significant difference in the survival of treated and control mice.

The number, percentages of animals with tumors, and their ages at death (latent periods) are summarized in Table 2. The 2 most important neoplasms are described in detail as follows.

Lung Tumors. Of the treated females, 17 (34%) developed 26 lung tumors; of these, 10 mice had 16 adenomas, 5 mice had 6 adenocarcinomas, and 2 mice had 2 adenomas and 2 adenocarcinomas. In the treated males, 24 (48%) developed 32 such neoplasms; of these, 16 mice had 22 adenomas, 7 had 7 adenocarcinomas, and 1 mouse had an adenoma and 2 adenocarcinomas. Macroscopically and histologically, all lung lesions were similar to those described earlier (15, 18).

Blood Vessel Tumors. Of the treated females, 16 (32%) developed blood vessel tumors; of these, 9 mice had angiomas, and 7 had angiosarcomas. The tissue distributions of angiomas were: liver, 4; ovaries, 4; lymph nodes, 3; whereas the distributions of angiosarcomas were: liver, 6; muscle, 1; fat, 1; spleen, 1; subcutis, 1. In the treated males, 15 (30%) developed such neoplasms; of these, 7 mice had angiomas, and 8 had angiosarcomas. The tissue distributions of angiomas were: liver, 5; lymph nodes, 2; whereas 8 angiosarcomas were found only in liver. Grossly and histologically, the blood vessel tumors were similar to those described earlier in this laboratory (13, 16, 20).

Other Tumors. A few other types of tumors were also found in the treated groups shown in Table 2. Since they occurred in low incidences, their appearance cannot be attributed to the treatment.

	_			Table	1										
	<i>Ir</i>	eatment and survi	val rate in	n AMPI	1-treat	ed and No. of	survivo	ors at t	the foll	e lowing	wk of	age	<u> </u>		
Group	Treatment	and sex	10	20	30	40	50	60	70	80	90	100	110	120 1	30
1	0.0625% AMPH in drinking water daily for life	50, F 50, M	50 50	50 49	50 48	44 45	42 42	39 38	35 29	27 20	22 8	16 2	6 1	1 1	
2	Untreated control	100, F 100, M	100 100	100 98	99 92	96 88	95 80	91 62	78 36	66 17	45 11	28 3	13 2	2 1	

Group Treatment no. and ex. M Lungs Blood vessels Other fisues Other fisues 1 0. and ex. M No. str ex. M No. str ex						umor distribution	in AM	PH-tr	eated and contr Anim	rol Swis Ials with	s mice 1 tumors of	
Group Treatment Cound asx Age at cleant, (w/) (w/) No. Type of tumor Age at cleant, (w/) 1 0.055% AMPH 50. F 17 34 90 (47-12) 16 32 22 (49-16) 10 10 11. (12) 10 10 11. (12) 10 10 11. (12) 10 10 11. (12) 10 10 10 11. (12) 10 10 10 10 10 11. (12) 10 10 10 10 11. (12) 10 10 10 10 11. (12) 10 10 10 11. (12) 11. (12) 11. (12) 10 10 10 10 10 10 10 10 10 10 10 10 11. (12) 11. (12) 11. (12) 11 10 10 10			Effortino			sbun		Blood	vessels		Other tissues	
1 0.062% MH 50. F 17 34 90 (47-121) 16 32 22 (49-116) 7 Malignant lymphomas 45(2,106,106) water raily for life 10 difference 2 Polypoid adenomas of glandular 116, 121 water raily for life 1 2 Polypoid adenomas of glandular 116, 121 water raily for life 1 2 Polypoid adenomas of glandular 111, 121 water raily for life 1 2 Polypoid adenomas of glandular 116, 121 1 Adenocarchical carcinoma of the set Adenocarchical adenoma of the set 1 1 Adenocarchical carcinoma of the set 1 2 2 Untreated 100. F 15 15 30 (47-119) 2 Adenocarchical carcinoma of the set 1 2 <th>Group</th> <th>Treatment</th> <th>no. and sex</th> <th>°. V</th> <th>%</th> <th>Age at Death ^a (wk)</th> <th>, Š</th> <th>%</th> <th>Age at death ^a (wk)</th> <th>Š</th> <th>Type of tumor</th> <th>Age at death (wk)</th>	Group	Treatment	no. and sex	°. V	%	Age at Death ^a (wk)	, Š	%	Age at death ^a (wk)	Š	Type of tumor	Age at death (wk)
Torritie 2 Polypoid adring and formas of gladular 100.110 Fitorastorma s.c. Fitorastorma s.c. 108 111.121 100.110 Solution Admocarcinoma of takin 99 99 99 99 Solution Admocarcinoma of takin 99 111.121 100.110 99 Solution Admocarcinoma of takin 99 100.110 100.110 99 Solution Admocarcinoma of takin 90 111.121 100.110 99 Solution 21 48 73 47.47 90 48 77.82.90.121 100.100 Solution 10 11 100.110 11 48 77.82.90.121 100.100 Solution 11 11 11 46 77.82.90.121 100.100 Solution 11 11 11 11 11 11 100.100 Solution 12 12 20 Malignant lymphomas 31 31 47.76.70.20 31 31 <t< td=""><td>-</td><td>0.0625% AMPH in drinking</td><td>50, F</td><td>1</td><td>34</td><td>90 (47–121)</td><td>16</td><td>32</td><td>92 (49–116)</td><td>~ 0</td><td>Malignant lymphomas</td><td>45, 102, 106, 106, 109, 116, 121</td></t<>	-	0.0625% AMPH in drinking	50, F	1	34	90 (47–121)	16	32	92 (49–116)	~ 0	Malignant lymphomas	45, 102, 106, 106, 109, 116, 121
2 Untreated 10 Fibroactiona of breast 10 50. M 24 48 78(-17-97) 15 Adenocarcinoma of breast 10 50. M 24 48 78(-17-97) 15 Malenocarcinoma of orest 10 50. M 24 48 78(-12) 15 30 78(47-97) 5 Malenocarcinoma of orest 10 50. M 24 48 78(-116) 15 30 78(47-97) 5 Malenocarcinoma of orest 10 50. M 24 48 78(-116) 15 30 78(-77, 85) 66 67(-66) 86 76(-77, 78) 86 77, 77, 73, 75, 75 86 77, 76, 79 86 77, 77, 73, 75, 75 86 76		water daily for life								20 10	Adrenocortical adenomas Polypoid adenomas of glandular stomach	106, 118 111, 121
2 Untreated 100. F 15 30 78 (47-97) 5 Malenocarcitoma of overy 105 2 Untreated 100. F 15 30 78 (47-97) 5 Malenocarcitoma of overy 105 2 Untreated 100. F 15 30 78 (47-97) 5 Malenocarcitoma of overy 105 2 Untreated 100. F 15 15 90 (67-116) 8 8 27 78, 75, 79, 85 2 Untreated 100. F 15 90 (67-116) 8 8 27, 76, 79, 85 86, 87, 89, 81 91, 41, 41, 41, 41, 41, 41, 41, 41, 41, 4											Fibrosarcoma, s.c. Adrenocortical carcinoma	108 109
2 Untreated 10. Adenocarcinoma of ovary 1 48. 77.82. 90.121 2 Untreated 100. F 15 30 78 (47-97) 5 Malignant lymphomas 48. 77.82. 90.121 2 Untreated 100. F 15 30 78 (47-97) 5 Malignant lymphomas 73 77.82. 90.121 2 Untreated 100. F 15 90 (67-116) 8 8 92 (74-119) 20 Malignant lymphomas 67 87.86.89.91 91.34, 76.79.85 2 Untreated 100. F 15 90 (67-116) 8 8 92 (74-119) 20 Malignant lymphomas 67 73.47.76.79.85 76 70 712 74.76.70 713 74.76.70 713 74.76.70 713 74.76.70 713 74.76.70 714 74.76.70 710 714.716 74.76.70 714 74.76.70 710.417.716 714 77.65.70 710.416 74.76.716 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>•</td> <td>Squamous cell carcinoma of skin</td> <td>99 70</td>										•	Squamous cell carcinoma of skin	99 70
50. M 24 48 79 (34-121) 15 30 78 (47-97) 5 Malignant lymphomas 48 77. 82. 90. 121 2 Untreated 100. F 15 30 78 (47-97) 5 Malignant lymphomas 87 78. 76. 79 85 72 2 Untreated 100. F 15 15 90 (67-116) 8 8 92 (74-119) 20 Malignant lymphomas 87, 38, 59, 51 91, 43, 71, 67, 78, 80, 51 91 91, 91, 102, 103 91, 91, 92, 103 91, 93, 102, 103 91, 91, 102, 103 91, 91, 91, 102, 103 91, 91, 91, 102, 103 91, 91, 91, 102, 103 91, 91, 91, 102 91, 91, 91, 102 91, 91, 91, 102 91, 91, 91, 103 91, 91, 91, 103 91, 91, 91, 103 91, 91, 91, 102 91, 91, 91, 102 91, 91, 91, 103 91, 91, 91, 103 91, 91, 91, 102 91, 91, 91, 102 91, 91, 91, 103 91, 91, 91, 103 91, 91, 91, 114, 114, 116 71, 114, 116 71, 114, 716 71, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76 76, 76											Adenocarcinoma of ovary Adenocarcinoma of ovary Adenocarcinoma of cecum	/9 105 81
2 Untreated 100. F 15 15 90 (67-116) 8 82 (74-119) 20 Malignant lymphomas 77 78, 78, 85 86, 87, 89, 80, 91 91, 90 (67, 102) 91, 90 (67, 102) 91, 90 (67, 102) 91, 91, 93, 93, 91 91, 94, 99, 102, 103 91, 94, 99, 102, 103 91, 94, 99, 102, 103 91, 94, 99, 102, 103 91, 94, 99, 102, 103 91, 94, 99, 102, 103 91, 94, 91, 114, 116 91, 94, 91, 114, 116 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 94, 91, 21, 03 91, 21, 114, 116 91, 21, 21, 03 91, 21, 21, 03 91, 21, 21, 03 91, 21, 21, 03 91, 21, 21, 21 91, 21 91, 21 91, 21 91, 21 91, 21 91, 21 91, 21 91, 21 91, 21			50, M	24	48	79 (34-121)	15	30	78 (47–97)	5	Malignant lymphomas	48, 77, 82, 90, 121
2 Untraated 100. F 15 15 90 (67-116) 8 82 (74-119) 20 Malignant lymphomas 86, 87, 76, 76, 76, 85, 93, 91 controls 100. F 15 15 90 (67-116) 8 8 27, 76, 76, 76, 76, 76, 76 controls 15 15 90 (67-116) 8 8 92 (74-119) 20 controls 101 12 103 101 102 103 104, 111, 114, 116 101 102 102 102 102 101 102 114, 114, 116 101 102 101 102 101 102 101, 114 101 102 10 102 101 102 101, 114 101 10 10 10 10 101 101 114 101 11 Adenocarcinoma of ovary 11 114 110 107, 114 110 101 11 Adenocarcinoma of ovary 11 110 110 111											Carcinoma of pituitary Adrenocortical carcinoma Polypoid adenoma of cecum	72 87 82
100, M 22 22 70 (40-124) 5 5 75 (57-92) 91 (4, 94, 91 (102, 114, 116, 116, 116, 116, 116, 116, 116	8	Untreated controls	100, F	15	15	90 (67–116)	ω	80	92 (74-119)	20	Malignant lymphomas	31, 33, 47, 76, 79, 85, 86, 87, 89, 89, 91,
2 Fibrosarcomas, s.c. 101, 102 2 Sex cord mesenchyma tumors 107, 114 1 Adenoacanthoma of ovary 11 1 Adenoacanthoma of ovary 110 1 Adenoacanthoma of thyroid 88 1 Adenoacarcinoma of functiona 127 1 Adenocarcinoma of duodenum 86 1 Adenocarcinoma of duodenum 86 1 Adenocarcinoma of duodenum 86 1 Adenocarcinoma of thyroid 64 1 Adenocarcinoma of functurer 86 1 Adenocarcinoma of functurer 86 1 Carcinoma of functurer 86 92, 112 92, 112 92, 112 2 Adenomas of thyroids 68, 92 2 Adenomas of thyroids 68, 92 2 Hepatomas 68, 92 2 1 Adenomas 68, 92 2 1 Adenomas 68, 92 3 1 Adenomas 68, 92 3 1 Adenomas 68, 92 3												91, 94, 99, 102, 103, 104, 111, 114, 116
2 Sex cord mesenchyma tumors 107,114 1 Adenoacanthoma of ovary 11 1 Adenoacanthoma of ovary 110 1 Adenocarcinoma of breast 127 1 Adenocarcinoma of duodenum 86 1 Adenocarcinoma of duodenum 86 1 Carcinoma of glandular stomach 64 92, 112 92, 112 92, 112 92, 112 28, 67, 78, 84, 91 92, 112 92, 112 28, 69, 92 92, 112 2 Adenoma of thyroids 69, 92 2 Adenoma of thyroids 68, 94 3 Adenoma of thyroids 68, 92 4 Adenoma of thyroids 68, 92 3 Adenoma of parathyroid 78										2	Fibrosarcomas, s.c.	101, 102
100. M 22 22 70 (40-124) 5 5 75 (57-92) 8 110 100. M 22 22 70 (40-124) 5 5 75 (57-92) 8 Malignant lymphomas 28, 67, 78, 84, 91 20. M 22 22 70 (40-124) 5 5 75 (57-92) 8 Malignant lymphomas 28, 67, 78, 84, 91 20. M 22 22 70 (40-124) 5 5 75 (57-92) 8 Malignant lymphomas 28, 67, 78, 84, 91 2 7 75 (57-92) 8 Malignant lymphomas 28, 67, 78, 84, 91 2 7 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 7 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 7 7 7 92, 112 92, 112 92, 112 2 7 7 7 7 92, 112 92, 112 2 7 7 7 94 enomas of thyroids 69, 92 92, 92 2 7 7 7 7 7 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>~ ~</td> <td>Sex cord mesenchyma tumors Adenoacanthoma of ovarv</td> <td>107, 114 71</td>										~ ~	Sex cord mesenchyma tumors Adenoacanthoma of ovarv	107, 114 71
1 Adenoma of thyroid 88 1 Adenocarcinoma of breast 127 1 Adenocarcinoma of breast 127 1 Adenocarcinoma of breast 127 1 Adenocarcinoma of breast 28, 62, 67, 78, 84, 91 2 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 69, 92 92, 112 92, 112 92, 112 92, 112 2 4denomas of thyroids 69, 92 2 4denomas of thyroids 68, 94 3 4denomas of thyroids 68, 94 1 Adenoma of parathyroid 78										-	Adenoma of ovary	110
1 Adenocarcinoma of breast 12/ 1 Adenocarcinoma of duodenum 86 1 Carcinoma of duodenum 86 1 Carcinoma of duodenum 86 2 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 2 75 (57-92) 8 Malignant lymphomas 28, 112 2 2 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 2 4denomas, s.c. 69, 92 92, 112 92, 112 2 4denomas of thyroids 69, 92 2 4denomas of thyroids 68, 94 2 1 Adenomas of thyroids 68, 94 93 1										-	Adenoma of thyroid	88
100. M 22 22 70 (40-124) 5 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 2 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 2 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 2 2 75 (57-92) 8 Malignant lymphomas 92, 112 2 2 76 nomas, s.c. 69, 92 22 40 nomas of thyroids 68, 94 2 1 Adenomas of thyroids 68, 94 92 112 112											Adenocarcinoma of breast Adenocarcinoma of duodenum	12/ B6
100, M 22 22 70 (40-124) 5 5 75 (57-92) 8 Malignant lymphomas 28, 62, 67, 78, 84, 91 92, 112 2 Fibrosarcomas, s.c. 69, 92 2 Hepatomas of thyroids 68, 94 1 Adenoma of parathyroid 78											Carcinoma of glandular stomach	3 29
2 Fibrosarcomas, s.c. 69, 92 2 Adenomas of thyroids 69, 92 2 Hepatomas 68, 94 1 Adenoma of parathyroid 78			100, M	22	52	70 (40–124)	5	S	75 (57-92)	8	Malignant lymphomas	28, 62, 67, 78, 84, 91, 92-112
2 Adenomas of thyroids 69, 92 2 Hepatomas 68, 94 1 Adenoma of parathyroid 78										2	Fibrosarcomas. s.c.	69.92
2 Hepatomas 68,94 1 Adenoma of parathyroid 78											Adenomas of thvroids	69, 92
1 Adenoma of parathyroid 78										10	Hepatomas	68, 94
										-	Adenoma of parathyroid	78

Table 2

DISCUSSION

The current study shows for the first time that the lifetime administration of 0.0625% AMPH in the drinking water of randomly bred albino Swiss mice, from 6 weeks of age, gave rise to lung and blood vessel tumors. The lung tumor incidence rose from 15 to 34% in females and from 22 to 48% in males, whereas the blood vessel tumor incidence increased from 8 to 32% in females and from 5 to 30% in males, compared with that in the untreated controls. The statistical analysis carried out by using Fisher's exact test (1) for 2 \times 2 tables shows that in females (p < 0.007) and males (p < 0.001) the lung tumor incidence was significantly higher in the treated groups. The incidence of blood vessel tumors is also significantly higher in treated females (p < 0.0002) and males (p < 0.00004), compared with that in control mice. Light microscopic examination of the lesions revealed the characteristic appearances of adenomas and adenocarcinomas of lungs and angiomas and angiosarcomas of blood vessels.

The commonly eaten cultivated mushroom A. bisporus contains up to 0.04% agaritine. The latter is a stable compound; however, enzymatically or under acidic conditions it breaks down to 4-hydroxymethylphenylhydrazine and L-glutamic acid (3). 4-Hydroxymethylphenylhydrazine is, on the other hand, an unstable product; therefore its acetylated form was synthesized, which is much more suitable for chronic tumorigenesis studies. Also, it has been shown in vitro, but not in vivo, that 4-hydroxymethylphenylhydrazine undergoes further changes and yields 4methylphenylhydrazine (3, 4). Interestingly, in a parallel study in this laboratory 4-methylphenylhydrazine hydrochloride was shown to induce tumors in Swiss mice (19). The estimated United States A. bisporus consumption totaled approximately 360,000,000 pounds in 1975 (21). In view of the carcinogenicity of these compounds, further studies obviously are needed to clarify this field of interest.

The present investigation is also part of the systematic approach to identify tumor-inducing hydrazine compounds in the environment and to study their mechanisms of action. Several of these chemicals are used in medicine, agriculture, and industry (14). In addition, a few were found to occur in nature in considerable quantities in tobacco and in some edible mushrooms (5-9, 11). Because of the carcinogenicity of this widely used class of hydrazine compounds, it seems advisable to warn against their use.

ACKNOWLEDGMENTS

The authors thank Lana Lippold for her technical assistance in the experimental work.

REFERENCES

- 1. Armitage, P. Statistical Methods in Medical Research, pp. 135-138. Oxford, England: Blackwell Scientific Publications Ltd., 1971.
- Daniels, E. G., Kelly, R. B., and Hinman, J. W. Agaritine, an Improved Isolation Procedure and Confirmation of Structure by Synthesis. J. Am. Chem. Soc., 83: 3333–3334, 1961.
- Gigliotti, H., and Levenberg, B. Studies on the γ-Glutamyltransferase of Agaricus bisporus. J. Biol. Chem., 239: 2274–2284, 1964.
- Kelly, R. B., Daniels, E. G., and Hinman, J. W. Agaritine: Isolation, Degradation, and Synthesis. J. Org. Chem., 27: 3229–3231, 1962.
- 5. Levenberg, B. Structure and Enzymatic Cleavage of Agaritine, a New Phenylhydrazide of L-Glutamic Acid Isolated from Agaricaceae. J. Am. Chem. Soc., 83: 503-504, 1961.
- List, P. H., and Luft, P. Nachweis und Gehaltsbestimmung von Gyromitrin in frischen Lorcheln. Arch. Pharm., 302: 143–146, 1969.
- Liu, Y. Y., and Hoffmann, D. Quantitative Chromatographic Determination of Maleic Hydrazide in Cigarette Smoke. Anal. Chem., 45: 2270– 2273, 1973.
- Liu, Y. Y., Schmeltz, I., and Hoffmann, D. Chemical Studies on Tobacco Smoke. Quantitative Analysis of Hydrazine in Tobacco and Cigarette Smoke. Anal. Chem., 46: 885–889, 1974.
- 10. The Merck Index, Ed. 9. Rahway, N. J.: Merck & Co., Inc., 1976.
- Schmeltz, I., Abidi, S., and Hoffmann, D. Tumorigenic Agents in Unburned Processed Tobacco; N-Nitrosodiethanolamine and 1,1-Dimethylhydrazine. Cancer Letters, 2: 125–132, 1977.
- 12. Toth, B. A Toxicity Method with Calcium Cyclamate for Chronic Carcinogenesis Experiments. Tumori, 58: 137-142, 1972.
- Toth, B. 1,1-Dimethylhydrazine (Unsymmetrical) Carcinogenesis in Mice. Light Microscopic and Ultrastructural Studies on Neoplastic Blood Vessels. J. Natl Cancer Inst., 50: 181–194, 1973.
- 14. Toth, B. Synthetic and Naturally Occurring Hydrazines as Possible Cancer Causative Agents. Cancer Res., 35: 3693–3697, 1975.
- Toth, B., Magee, P. N., and Shubik, P. Carcinogenesis Study with Dimethylnitrosamine Administered Orally to Adult and Subcutaneously to Newborn BALB/c Mice. Cancer Res., 24: 1712–1721, 1964.
- Toth, B., and Malick, L. Scanning Electron Microscopic Study of the Surface Characteristics of Neoplastic Endothelial Cells of Blood Vessels. J. Pathol., 118: 59–63, 1976.
- Toth, B., and Nagel, D. Tumorigenicity of the N'-Acetyl Derivative of 4-Hydroxymethylphenylhydrazine, an Ingredient of Agaricus bisporus. Proc. Am. Assoc. Cancer Res., 18: 15, 1977.
- Toth, B., and Shimizu, H. 1-Carbamyl-2-phenylhydrazine Tumorigenesis in Swiss Mice. Morphology of Lung Adenomas. J. Natl. Cancer Inst., 52: 241–251, 1974.
- Toth, B., Tompa, A., and Patil, K. Tumorigenic Effect of 4-Methylphenylhydrazine Hydrochloride in Swiss Mice. Z. Krebsforsch. Klin. Onkol., 89: 245–252, 1977.
- Toth, B., and Wilson, R. B. Blood Vessel Tumorigenesis by 1,2-Dimethylhydrazine Dihydrochloride (Symmetrical). Gross, Light and Electron Microscopic Descriptions. I. Am. J. Pathol., 64: 585–600, 1971.
- United States Department of Agriculture, Statistical Reporting Service, Crop Reporting Board, Mushrooms, Vg 2-1-2, pp. 1-4, Washington, D. C., 1976.